Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Recap by typeshit. Full story at Briefs Finance.
Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Belga reports the number of seized weight loss drugs in Belgium went up again, with officials concerned about an unofficial parallel market.
Clinics took about 60% of supply, and one Seoul clinic got more Mounjaro than 174 hospitals combined. The health ministry warns of sanctions and criminal referrals.
The Partnership for Safe Medicines calls the compounding illegal and risky, as RFK Jr. pitches a state-regulated marketplace for peptides like BPC-157, per RAPS.
A Tamil-language segment looks at whether weight loss injections can harm vision, featuring SIMS Hospital. Tap through for the doctor's take.
Harvard's Pieter Cohen and Johns Hopkins' Caleb Alexander advise against unapproved injectable peptides as HHS reportedly plans to let pharmacies compound some.
Loading…